Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic—World Scleroderma Foundation preliminary advice for patient management’

Snarskaya, Elena S.; Vasileva, Kseniia D.

doi:10.1136/annrheumdis-2020-219489

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, the corticosteroids’ initiation or cessation among rheumatic patients with COVID-19 is left to the decision of experienced clinicians, with a need for more precisely defined criteria. [ 19 ]…”

Section: Discussionmentioning

confidence: 99%

The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis

Adrovic,

Yıldız,

Haşlak

et al. 2022

Arch Rheumatol

View full text Add to dashboard Cite

Objectives: This study aimed to explore the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic among patients with juvenile systemic sclerosis (JSS). Patients and methods: Twenty-seven patients (22 females, 5 males; mean age: 20 years; range, 17 to 22 years) diagnosed with JSS and followed up at the department of pediatric rheumatology were included in the cross-sectional study. A web-based survey was performed by focusing on patients’ complaints, accessibility to health care, and compliance with routine treatment from January 1, 2021, to January 10, 2021. Results: Five (18.5%) patients had deterioration of the disease, while six (22.2%) patients reported irregular usage of their routine scleroderma treatment during the last six months. Nine (33.3%) patients had missed their routine clinic control since the proclamation of the SARS-CoV-2 pandemic. Seven (25.9%) patients had household contact with coronavirus disease 2019 (COVID-19). Four (14.8%) patients were diagnosed with COVID-19, and only one (3.7%) was hospitalized. Nine patients were under biological treatment (tocilizumab); however, only one of them was diagnosed with COVID-19. Conclusion: The COVID-19 pandemic has not significantly disrupted the medical care of JSS patients. Telemedicine could be an acceptable option for JSS patients disenabled to come to the hospital.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis

Adrovic,

Yıldız,

Haşlak

et al. 2022

Arch Rheumatol

View full text Add to dashboard Cite

show abstract

“…Response to: 'Correspondence on 'Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management'' by Snarskaya and Vasileva We read with great interest the response from Snarskaya and Vasileva. 1 A second wave of SARS-CoV-2 infection is now a global reality 2 : since the publication of the World Scleroderma Foundation preliminary advice on the management on systemic sclerosis (SSc) patients during the first COVID-19 pandemic, 3 growing evidence has accumulated on COVID-19 affected SSc patients. 4 Up to 22 June, at the end of the first wave, 25 cases of SSc-COVID-19 were published in the literature, most of them undergoing immunosuppressant treatment with corticosteroids (CCS), conventional synthetic disease modifying antirheumatic drugs (csDMARDs) (methotrexate or mycophenolate mofetil) or biological DMARD (bDMARDs) (rituximab or tocilizumab) and with a variable outcome.…”

mentioning

confidence: 99%

Response to: ‘Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management’’ by Snarskaya and Vasileva

Bruni

Matucci‐Cerinic

2021

Ann Rheum Dis

View full text Add to dashboard Cite

Correspondence responseCOVID-19 convalescent plasma, given the promising results shown in a small cohort of patients. 15 We herein agree with the suggestions delivered from other societies and consider the possible role of PCR-retesting and anti-COVID-19 antibodies measuring before restarting IMS treatment in SSc-patients with initially positive PCR test. This preliminary consideration will be updated once data from larger initiatives, such as the EUSTAR COVID-19 registry, the EULAR COVID-19 database and the global alliance COVID-19 registry, will provide more robust evidences.

show abstract

Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies

Calderón-Parra

Múñez-Rubio

Sanchez

et al. 2021

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background Our objective is to describe the presentation and complications, including relapses, of COVID-19 in patients under anti-CD20 treatments. In addition, to describe viral clearance and determine the safety of reintroducing anti-CD20 treatment. Methods Retrospective cohort study of 422 patients under anti-CD20 treatment that was administered from January 1, 2019, to December 31, 2020. Results Fifty-seven patients were diagnosed of COVID-19 (13.5%). 25 patients (43.9%) required hospital admission. 5 patients died (8.8%), 10 developed severe COVID-19 and acute respiratory distress syndrome. Mortality rate was higher among patients infected during the first 3 months following the last dose of anti-CD20 (14.7% vs 0%, p=0,046).The median time of persistence of positive RT-PCR was 22 days (IQR 13-40). Nine out of 52 survivors (17.3%) presented relapses. All of them received the last dose of anti-CD20 less than 6 months before the COVID-19 episode. Clinical presentation was fever (n=8; 88.9%), dyspnea (n=7; 77.8%), cough (n=7; 77.8%), worsening of previous infiltrates (n=5; 55.6%) and new pulmonary infiltrates (n=8; 88.9%). An increase in lymphocytes with CD4/CD8 ratio inversion was observed in all cases. Among the 25 patients who resumed anti-CD20 drug, 4 (16.0%) presented relapses vs 5/28 among those who did not (17.9%), (p=0.857). Conclusion Patients infected with SARS-CoV-2 during the 6 months after anti-CD20 administration had a worse outcome and a higher mortality rate. The duration of infectivity may be longer. Relapses of COVID-19 occurred in more than 15% and were associated with viral replication. Once the infection is resolved, it is safe to restart treatment with anti-CD20.

show abstract

Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic—World Scleroderma Foundation preliminary advice for patient management’

Cited by 3 publications

References 9 publications

The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis

The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis

Response to: ‘Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management’’ by Snarskaya and Vasileva

Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies

Contact Info

Product

Resources

About